Welcome to our dedicated page for AVROBIO news (Ticker: AVRO), a resource for investors and traders seeking the latest updates and insights on AVROBIO stock.
AVROBIO, Inc. (AVRO) is a clinical-stage biopharmaceutical company pioneering gene and cell therapies for rare diseases and cancer. This page aggregates official announcements, clinical trial updates, and strategic developments critical to understanding the company's progress.
Investors and researchers will find verified updates on therapy pipelines, regulatory milestones, and scientific collaborations. Content spans phase trial results, manufacturing advancements, and partnership announcements, providing a holistic view of AVROBIO's position in the gene therapy landscape.
All materials are sourced from company filings and accredited industry publications. Bookmark this page for streamlined access to AVROBIO's latest developments, or subscribe for real-time updates on groundbreaking therapeutic innovations.
AVROBIO announced significant advancements in its clinical trials for gene therapies targeting lysosomal disorders. In the Phase 2 FAB-GT trial for Fabry disease, the first patient treated showed a complete 100% reduction of toxic substrate in kidney biopsies. Furthermore, the Phase 1/2 trial for Gaucher disease type 1 revealed notable decreases in key biomarkers. Positive outcomes were also noted for cystinosis patients, who remain off standard medication. With ongoing enrollment and promising results, AVROBIO aims to dose a total of 30 patients across all programs by year-end.
AVROBIO, a clinical-stage gene therapy company, has granted stock options to new employees including 10,250 shares to a new staff member and 130,000 shares to Chief Medical Officer Diana M. Escolar, M.D. Both grants, approved by the Compensation Committee, were made to incentivize employment acceptance and have a 10-year term. The exercise price is set at $14.55 per share, based on the closing stock price on February 1, 2021. Vesting occurs over four years, incentivizing continued service with the company.
AVROBIO, Inc. (Nasdaq: AVRO), a clinical-stage gene therapy company, will host a virtual investor event on February 8, 2021, to share new clinical data from its programs targeting Fabry disease, cystinosis, and Gaucher disease type 1, presented at the 17th annual WORLD Symposium. The company will also conduct medical symposia discussing ex vivo lentiviral gene therapy advancements. Key presentations include updates on various clinical trials, showcasing the company's commitment to delivering innovative therapies for genetic diseases.
AVROBIO, Inc. (Nasdaq:AVRO), a clinical-stage gene therapy company, announced that Azadeh Golipour, VP of Manufacturing Operations, will present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit on January 29, 2021, at 11:30 a.m. ET. AVROBIO focuses on personalized gene therapy aimed at treating genetic diseases with a single dose. Its pipeline includes clinical programs in Fabry disease, Gaucher disease type 1, and cystinosis, utilizing the innovative plato® gene therapy platform. The company, headquartered in Cambridge, Mass., aims to enhance therapeutic outcomes in hard-to-reach tissues.
AVROBIO, a clinical-stage gene therapy company, has appointed Dr. Diana Escolar as Chief Medical Officer. Dr. Escolar is recognized for her expertise in rare diseases, particularly lysosomal and neurogenetic disorders. The company plans to expand clinical trials and regulatory strategies for its gene therapy programs, notably targeting Fabry disease and Hunter syndrome. Dr. Escolar's extensive background in pediatric neurogenetic diseases is expected to enhance AVROBIO's initiatives. The firm aims to revolutionize treatment options for genetic diseases through its innovative gene therapy platform.
AVROBIO, a clinical-stage gene therapy company (NASDAQ: AVRO), announced that CEO Geoff MacKay will present at the ICR Conference 2021 on January 14 at 11:30 a.m. ET. The presentation can be accessed via live webcast on AVROBIO's website and an archived recording will be available for 30 days. AVROBIO aims to provide personalized gene therapy for various genetic diseases, powered by its plato® gene therapy platform. The company is focused on advancing treatments for Fabry disease, Gaucher disease type 1, and cystinosis, among others.
AVROBIO, Inc. (Nasdaq: AVRO) announced the grant of non-statutory stock options for 85,250 shares of common stock to three new employees as inducement awards. The options, approved by the Board's Compensation Committee, have an exercise price of $14.57 per share, equal to the stock's closing price on the grant date (Jan. 4, 2021). These awards will vest over four years, contingent on continued employment. AVROBIO focuses on gene therapy for genetic diseases, with programs targeting Fabry disease, Gaucher disease, cystinosis, among others.
AVROBIO, a clinical-stage gene therapy company, announced granting a non-statutory stock option to a new employee for the purchase of up to 63,000 shares under its 2019 Inducement Plan. This option was approved by the Compensation Committee and has an exercise price of $13.80, reflecting the closing stock price on the grant date of Dec. 1, 2020. The option vests over four years with a 10-year term, contingent on the employee's continued service. AVROBIO focuses on personalized gene therapies for genetic diseases and operates a pipeline addressing various conditions.
AVROBIO, Inc. (NASDAQ: AVRO) has completed a public offering of 5,000,000 shares, generating gross proceeds of $75 million. The underwriters have a 30-day option to purchase an additional 750,000 shares. The funds will support the company’s gene therapy programs for conditions like Fabry disease and Gaucher disease, as well as manufacturing and research activities. The offering was registered under Form S-3, and investors can access the final prospectus on the SEC's website.
AVROBIO, Inc. has announced the pricing of a public offering of 5,000,000 shares of common stock at $15.00 per share, aiming for gross proceeds of approximately $75 million. The offering includes a 30-day option for underwriters to buy an additional 750,000 shares. Proceeds from the offering will support ongoing programs in various genetic diseases and fund R&D activities. The offering is expected to close on or about Nov. 24, 2020. Morgan Stanley, Cowen, Wells Fargo Securities, and Barclays are acting as joint book-running managers.
